Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
Georgina V LongCaroline RobertMarcus O ButlerFelix CoutureMatteo S CarlinoSteven O'DayVictoria AtkinsonJonathan S CebonMichael P BrownStéphane DalleAndrew G HillGeoffrey T GibneySteven McCuneAlexander M MenziesCuizhen NiuNageatte IbrahimBlanca Homet MorenoAdi DiabPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Pembrolizumab 200 mg Q3W plus ipilimumab 50 mg Q6W or 100 mg Q12W demonstrated antitumor activity above the predefined threshold; pembrolizumab plus ipilimumab 50 mg Q6W had lower incidence of grade 3-5 TRAEs than the predefined threshold, suggesting a reduction in toxicity.See related commentary by Jameson-Lee and Luke, p. 5153.